Company / Total Assets
Fulcrum Therapeutics, Inc. Total Assets History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$366.3M
FY2025
5-year range
$226.7M / $366.3M
FY2021-FY2025
Trend
+40.5%
vs FY2024
Sector context
#164 of 214
Health Care
What the data says
Fulcrum Therapeutics, Inc.'s total assets of $366M is lower than 77% of companies in the Health Care sector (FY2025). Total Assets has increased for 3 consecutive years, from $227M in FY2022 to $366M in FY2025.
Based on SEC 10-K filings.
$366M in FY2025 with a 5-year CAGR of +23.1%.
Improved from $258M to $366M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +17.3%
- 5-Year CAGR
- +23.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 214This company $366.3M Sector average $7.5B
▼
-95.1% below sector average
Key checks
Key Insights
- Fulcrum Therapeutics, Inc.'s total assets has grown for 3 consecutive years.
- 5-year CAGR of +23.1%, indicating consistent growth.
- In FY2025, total assets increased 40.5% year-over-year.
- Ranks #164 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $366.3M | +40.5% |
| FY2024 | $260.7M | +1.2% |
| FY2023 | $257.7M | +13.7% |
| FY2022 | $226.7M | -3.5% |
| FY2021 | $235.0M | +81.4% |
| FY2020 | $129.6M | +17.3% |
| FY2019 | $110.4M | +28.8% |
| FY2018 | $85.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026